Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

Original reporting
Published Nov 6, 2026, 7:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Astrana Health (ASTH) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ASTHBullishHigh
01

Why it matters

Strong earnings and cash flow may trigger buying interest; however, Medicaid attrition and cost pressures remain risks.

02

Market read

First‑report earnings release with material financial metrics; likely to move the stock in after‑hours trading.

03

What to watch

Potential Medicaid attrition and exchange membership losses could pressure margins later.

Relevance 8/10Novelty 8/10Timing: after market today

Background

Astrana Health reported Q3 2026 results, detailing revenue, EBITDA, free cash flow, debt repayment, and strategic initiatives.

Company-level read

Ticker impact

$ASTHBullishMedium confidence
Context

Q3 2026 earnings call disclosed record $1.02B revenue and $77.2M adjusted EBITDA, new guidance and free cash flow figures.

Expected impact

likely upward pressure as investors price in strong earnings and cash flow generation

Evidence & confidence

Revenue and EBITDA both topped guidance; free cash flow strong and debt reduction improves balance sheet.

Market effects

Highlights strength in the managed‑care and risk‑bearing health services sector.

Positive for U.S. health‑care stocks, especially those with similar capitation models.

Limited to health‑care investors; no broader macro effect.

Counterpoint

If guidance falls short of market expectations despite absolute growth, the stock could face a pullback.

Key entities

  • Astrana Health

    Provider of risk‑bearing health‑care services.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.